Roger W. Blamey

Q: What Schools Are Affiliated With Roger W. Blamey

Roger W. Blamey is affiliated with the following schools: University of Nottingham, University of Melbourne, University of Cambridge

Roger W. Blamey's AcademicInfluence.com Rankings

Roger W. Blamey

Philosophy

#7656

World Rank

#10897

Historical Rank

Logic

#4702

World Rank

#6023

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Roger W. Blamey's Degrees

Doctorate Medicine Stanford University

Why Is Roger W. Blamey Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roger W. Blamey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
The Nottingham prognostic index in primary breast cancer (2005) (904)
A prognostic index in primary breast cancer. (1982) (715)
High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses (2005) (596)
Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. (2000) (576)
Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. (2008) (496)
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes (2009) (473)
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up (1992) (471)
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. (2001) (422)
The psychological impact of immediate rather than delayed breast reconstruction. (2000) (421)
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. (2002) (334)
Confirmation of a prognostic index in primary breast cancer. (1987) (316)
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. (1991) (237)
Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. (1996) (221)
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. (1999) (214)
Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. (2007) (212)
Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity? (1999) (208)
Early-onset breast cancer--histopathological and prognostic considerations. (1997) (207)
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. (2006) (207)
Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. (2008) (206)
Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy (1994) (201)
Screening interval breast cancers: mammographic features and prognosis factors. (1996) (198)
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. (1995) (183)
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. (1990) (170)
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. (2013) (169)
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. (1995) (167)
p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. (1993) (163)
Factors influencing local recurrence after excision and radiotherapy for primary breast cancer (1989) (162)
Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? (1995) (159)
The cosmetic outcome in early breast cancer treated with breast conservation. (1999) (151)
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. (1986) (147)
Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy (2004) (146)
Immunocytochemical localization of BCL‐2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy (1994) (146)
Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. (2006) (146)
Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. (1992) (145)
Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. (1988) (143)
Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. (1994) (141)
Estrogen receptor assay in primary breast cancer and early recurrence of the disease. (1978) (140)
Histologic Grading of Breast Cancer: Linkage of Patient Outcome with Level of Pathologist Agreement (2000) (137)
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. (2003) (137)
Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. (1978) (134)
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. (1997) (134)
QUANTITATIVE OESTRADIOL RECEPTOR VALUES IN PRIMARY BREAST CANCER AND RESPONSE OF METASTASES TO ENDOCRINE THERAPY (1981) (129)
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. (2000) (129)
Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. (1987) (123)
Tubular carcinoma of the breast: further evidence to support its excellent prognosis. (2010) (122)
c-erbB-4 protein expression in human breast cancer (2000) (115)
Expression of epidermal growth factor receptor in breast carcinoma. (1990) (113)
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. (1986) (109)
An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. (1991) (105)
ONCOPOOL - a European database for 16,944 cases of breast cancer. (2010) (103)
Oestrogen-regulated genes in breast cancer: association of pLIV1 with lymph node involvement. (1994) (103)
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer. (2007) (102)
Clinical and histological predictors of contralateral breast cancer. (1999) (102)
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. (1995) (101)
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) (2003) (101)
p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. (1992) (99)
RELATIONSHIP OF ŒSTROGEN-RECEPTOR STATUS TO SURVIVAL IN BREAST CANCER (1979) (97)
A monoclonal antibody, NCRC‐11, raised to human breast carcinoma. 1. Production and immunohistological characterization (1984) (97)
Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. (1989) (96)
Relationship between primary breast tumor receptor status and patient survival (1980) (95)
Male breast cancer: pathological and immunohistochemical features. (1997) (94)
The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. (2009) (94)
The prognosis of small primary breast cancers. (1999) (91)
Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. (1985) (87)
Circulating immune complexes in patients with breast cancer. (1977) (87)
Estradiol induction of retinoic acid receptors in human breast cancer cells. (1993) (87)
Helix pomatia and Ulex Europeus lectin binding in human breast carcinoma (1987) (87)
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival (1998) (86)
E-cadherin as a prognostic indicator in primary breast cancer (2001) (86)
A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. (1991) (84)
Goserelin depot in the treatment of premenopausal advanced breast cancer. (1992) (83)
Oestrogen-receptor status and sites of metastasis in breast cancer. (1981) (83)
Prognostic significance of synchronous and metachronous bilateral breast cancer (2001) (82)
Cytological grading of breast carcinoma—a feasible proposition? (1990) (81)
Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. (1987) (80)
EUSOMA accreditation of breast units. (2006) (76)
Up‐regulation of the protein tyrosine phosphatase SHP‐1 in human breast cancer and correlation with GRB2 expression (2000) (76)
Guidelines on endocrine therapy of breast cancer EUSOMA. (2002) (74)
Immunocytochemical localization of estrogen receptor in human breast tissue. (1988) (74)
Subcutaneous mastectomy for primary operable breast cancer (1984) (74)
In situ carcinoma of the breast. (1989) (74)
Metallothionein expression in human breast cancer. (1995) (73)
Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. (1996) (73)
Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. (1995) (73)
Prognostic factors in breast cancer -- the formation of a prognostic index. (1979) (72)
Cosmetic assessment of breast-conserving surgery for primary breast cancer. (1999) (71)
Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. (1993) (70)
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers (2010) (69)
Patient evaluation of cosmetic outcome after conserving surgery for treatment of primary breast cancer. (1999) (68)
The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). BASO Breast Specialty Group. (1998) (65)
Screening women aged less than 50 years with a family history of breast cancer. (1998) (65)
A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients (2010) (64)
The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. (2002) (63)
A comparison of the use of the ‘Tru‐Cut’ needle and fine needle aspiration cytology in the pre‐operative diagnosis of carcinoma of the breast (1978) (58)
Reading the prognosis of the individual with breast cancer. (2007) (57)
Chemotherapy‐induced differential changes in lymphocyte subsets and natural‐killer‐cell function in patients with advanced breast cancer (1993) (55)
Immunocytochemical investigation of intermediate filament proteins and epithelial membrane antigen in spindle cell tumours of the breast (1988) (52)
Carcinoma of the breast imaged by nuclear magnetic resonance (NMR). (1979) (52)
4. The design and clinical use of the nottingham prognostic index in breast cancer (1996) (51)
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. (1996) (50)
The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology (2009) (50)
Occult axillary lymph-node micrometastases in breast cancer (1990) (49)
Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. (1992) (48)
Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. (1987) (47)
Prognostic significance of serum c-erbB-2 protein in breast cancer patients (2005) (47)
Timing breast cancer surgery (1991) (45)
Screening for breast cancer (1994) (45)
Microdochectomy for single‐duct discharge from the nipple (1988) (45)
Management of physiological gynaecomastia with tamoxifen. (2004) (45)
Subcutaneous mastectomy for primary breast cancer and ductal carcinoma in situ. (1997) (44)
Steroid receptors in early breast cancer: value in prognosis. (1981) (44)
Results from a seven-year programme of breast self-examination in 89,010 women. (1989) (44)
MAMMOGRAPHY IN SYMPTOMATIC BREAST DISEASE (1989) (43)
c-myc oncogene product expression and prognosis in operable breast cancer. (1989) (43)
Estrogen receptors and breast cancer. (1981) (41)
Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. (1985) (41)
Survival patterns in hormone treated advanced breast cancer (1986) (40)
Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer. (1984) (40)
Loss of Heterozygosity in Bilateral Breast Cancer (2000) (39)
Differential expression of oestrogen regulated genes in breast cancer. (1995) (38)
Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. (1997) (37)
Relationship of oestrogen-receptor status to survival in breast cancer. (1979) (37)
Calcium excretion (CaE) in metastatic breast cancer (1983) (36)
Staging breast cancer: role of bone scanning. (1977) (36)
Prediction of lymph node involvement in breast cancer (1991) (35)
The increasing importance of chronic rejection as a cause of renal allograft failure (1989) (35)
Bone scanning: Its lack of value in the follow‐up of patients with breast cancer (1979) (34)
The late results of renal transplantation and the importance of chronic rejection as a cause of graft loss. (1989) (34)
Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers. (1986) (34)
IMMUNE COMPLEXES AND PROGNOSIS OF HUMAN BREAST CANCER (1978) (34)
The relationship of "high risk" mammographic patterns to histological risk factors for development of cancer in the human breast. (1990) (34)
Use of older patients as cadaveric kidney donors (1988) (33)
Preoperative diagnosis in carcinoma of the breast (1977) (33)
Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? (2004) (32)
Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates (1997) (32)
An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. (1990) (32)
Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes (1996) (32)
The use of monoclonal antibody 791T/36 in the immunoscintigraphy of primary and metastatic carcinoma of the breast. (1984) (30)
Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. (1989) (30)
The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. (1993) (29)
Early experience in breast cancer screening: emphasis on development of protocols for triple assessment (1993) (28)
Endocrine treatment of physiological gynaecomastia (2003) (28)
Subcutaneous mastectomy with implant reconstruction: cosmetic outcome and patient satisfaction. (2000) (27)
Influence of anti-oestrogens on the specific binding in vitro of (3H)oestradiol by cytosol of rat mammary tumours and human breast carcinomata. (1975) (27)
The breast pain clinic: a rational approach to classification and treatment of breast pain. (1987) (27)
A double‐blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain (1986) (26)
Carcinoembryonic antigen (CEA): its role as a tumour marker in breast cancer. (1981) (25)
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer. (1988) (25)
Value of Contralateral Surveillance Mammography for Primary Breast Cancer Follow-up (2000) (25)
Transforming growth factor-alpha and endocrine sensitivity in breast cancer. (1994) (24)
Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer. (1986) (24)
Transplantation, immunosuppression and plasmapheresis in Goodpasture's syndrome. (1978) (24)
A prospective study of patient choice in treatment for primary breast cancer. (1991) (23)
Effect of human leucocyte antigen matching on the incidence of acute rejection in renal transplantation (1994) (23)
Zoladex® plus tamoxifen versus zoladex® alone in pre- and peri-menopausal metastatic breast cancer (1990) (23)
Breast self-examination for the early detection of breast cancer. (1988) (21)
The management of locally advanced carcinoma of the breast by Nolvadex (tamoxifen): a pilot study. (1984) (21)
Characteristics of cadaveric renal allograft recipients developing chronic rejection. (1990) (21)
Phenotypic similarities in bilateral breast cancer (2004) (20)
MONITORING THE FUNCTION OF RENAL TRANSPLANTS (1977) (20)
An observation of DNA ploidy, histological grade, and immunoreactivity for tumour‐related antigens in primary and metastatic breast carcinoma (1989) (20)
Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. (1993) (20)
Metallothionein expression in human breast cancer (1992) (20)
The Primary Implantation of Human Tumours to the Hamster Cheek Pouch (1971) (20)
Reticuloendothelial activity during the growth of rat sarcomas. (1969) (19)
Clinical Radiology of the Breast (1990) (19)
Safe selection criteria for breast conservation without radical excision in primary operable invasive breast cancer. (1995) (19)
Natural killer cells in renal allograft rejection (1984) (19)
Mammography in the pre-operative assessment and post-operative surveillance of patients treated by excision and radiotherapy for primary breast cancer. (1990) (18)
MEDICAL RESEARCH COUNCIL TRIAL OF ANTILYMPHOCYTE GLOBULIN IN RENAL TRANSPLANTATION: A MULTICENTER RANDOMIZED DOUBLE‐BLIND PLACEBO CONTROLLED CLINICAL INVESTIGATION (1983) (18)
Preliminary results of the Nottingham breast self‐examination education programme (1987) (18)
Identification of a monoclonal antibody-defined breast carcinoma antigen in body fluids. (1987) (18)
Are backup arteriovenous fistulae necessary for patients on continuous ambulatory peritoneal dialysis? (1993) (18)
Overexpression of Cyclin D 1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer 1 (1999) (18)
The relationship of oestradiol receptor (ER) and histological tumour differentiation with prognosis in human primary breast carcinoma. (1980) (17)
The prediction of local or regional recurrence after simple mastectomy for operable breast cancer (1985) (17)
INK 4 a Gene Expression and Methylation in Primary Breast Cancer : Overexpression of p 16 INK 4 a Messenger RNA Is a Marker of Poor Prognosis 1 (2000) (16)
A comparison of danazol and placebo in the treatment of adult idiopathic gynaecomastia: results of a prospective study in 55 patients. (1991) (16)
Salivary cortisol and dehydroepiandrosterone sulphate levels in postmenopausal women with primary breast cancer. (1983) (15)
Estimation of Prognosis of the Individual with Primary Breast Cancer and its Applications (2002) (14)
Cathepsin D in primary breast carcinoma: Adverse prognosis is associated with expression of cathepsin D in stromal cells (2004) (14)
An evaluation of transmission spectroscopy (lightscanning) in the diagnosis of symptomatic breast lesions. (1987) (14)
The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. (1988) (14)
Plasma spermidine concentrations in patients with tumours of the breast or prostate or testis. (1980) (13)
Patterns of flap recurrence following mastectomy (1985) (13)
BREAST CANCER, TAMOXIFEN, AND SURGERY (1988) (13)
Initial results from a programme of breast self-examination. (1983) (13)
Serum ferritin as a marker of therapeutic response in stage III and IV breast cancer. (1990) (13)
Mammographic parenchymal patterns: value as a predictor of hormone dependency and survival in breast cancer. (1985) (12)
ABC of Breast Diseases: Screening for Breast Cancer (1994) (12)
Spleen Weight in Rats During Tumour Growth and in Homograft Rejection (1971) (11)
Ductal Carcinoma In-Situ Of The Breast: A new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression (1992) (11)
Development of a protocol for evaluation of mammographic surveillance services in women under 50 with a family history of breast cancer. (2001) (11)
The BASO II trial of adjuvant radiotherapy. V. None and tamoxifen. V. None in small, node negative, grade I tumours (2001) (11)
Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma (1991) (10)
Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer. (1989) (10)
A controlled trial of danazol in the treatment of multiple recurrent breast cysts (1986) (10)
Availability of organs for transplantation: a three year study. (1986) (10)
Characterisation of breast skin temperature rhythms of women in relation to menstrual status. (1981) (10)
Blood transfusion and renal allograft survival. (1978) (9)
Therapeutic potential of the lh-rh agonist zoladex (ICI 118630) in the treatment of advanced breast cancer in pre and postmenopausal women (1984) (9)
Density of lymphocytic infiltration of primary breast cancer does not affect short-term disease-free interval or survival. (1990) (8)
P107 The ‘ZEBRA’ study: ‘Zoladex’ (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less (1998) (8)
The role of selective non-steroidal aromatase inhibitors in future treatment strategies. (1997) (8)
Tumour epithelial cellularity and quantitative oestrogen receptor values in primary breast cancer. (1983) (8)
Update of the BASO II trial of primary treatment of tumours of excellent prognosis (2004) (8)
TRIALS OF ADJUVANT CHEMOTHERAPY IN BREAST CANCER (1979) (8)
Biological and clinical aspects of oestrogen receptor measurements in rapidly progressing breast cancer (1984) (8)
PP-3-20 local excision with a 10 mm margin as sole treatment for ductal carcinoma in situ (dcis) of the breast (1996) (8)
Postoperative radiotherapy following mastectomy for high-risk breast cancer. A randomised trial. (2002) (8)
Zoladex in advanced breast cancer. (1989) (8)
Local anaesthetic and steroid combined injection therapy in the management of non-cyclical mastalgia. (2004) (8)
Mammographic and pathological features of breast cancer detected at first incident round screening (1997) (8)
Selection of Primary Breast Cancer Patients for Adjuvant Endocrine Therapy – is Oestrogen Receptor Alone Adequate? (2004) (7)
Selection for adjuvant systemic therapy using the Nottingham prognostic index (NPI) (1993) (7)
Complications in the management of breast disease (1986) (7)
Pure antioestrogens in breast cancer - experimental and clinical observations (1994) (7)
Oestrogen receptors in primary breast cancer. (1985) (7)
A comparison of fine needle aspiration cytology and tru-cut tissue biopsy in the diagnosis of acute renal allograft rejection. (1986) (7)
The use of 125 I-fibrinogen in the detection of renal allograft rejection. Rat model. (1973) (6)
Micrometastases in bone marrow in patients with breast cancer. (1987) (6)
Evaluation of animal models of chronic vascular rejection. (1993) (6)
A suggested classification of breast pain. (1979) (6)
Experiments in tumour immunology (1968) (6)
Prolactin and breast skin temperature rhythms in postmenopausal women with primary breast cancer. (1983) (6)
OBSERVATIONS ON THE REMOVAL OF CELLS AND PARTICIPATE MATTER FROM THE HAMSTER CHEEK POUCH (1968) (6)
A simple index to predict prognosis independent of axillary node information in breast cancer: comment. (1998) (6)
Diagnosis by team work: an approach to conservatism. (1991) (6)
The role of the radiologist in breast diagnosis: a surgeon's personal view. (1998) (6)
The effect of isogenic lymphoid cell on primary sarcomas in the rat. (1969) (6)
Node negative breast cancer. (1990) (5)
Phenotypic drift does not happen but lots of interesting things do (1993) (5)
86. Pharmacokinetics, systemic and antitumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer (1995) (5)
Clinical studies with the specific ‘pure’ antioestrogen ICI 182780 (1996) (5)
Bilateral breast carcinomas: do they have similar mammographic features? (1999) (5)
Post-mastectomy radiotherapy in patients at high risk of locoregional recurrence: A randomized trial (1992) (5)
Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting? (2005) (4)
The 1989 Walter Hubert lecture. Does biological understanding influence surgical practice? (1989) (4)
B.I.G.--brother is watching you? (2000) (4)
Long-term follow up of patients treated with a single course of danazol for recurrent breast cysts. (1989) (4)
Renal allotransplantation in the rat: method and histological findings. (1974) (4)
A comparison of the characteristics and prognosis of screen detected and symptomatic breast cancers (1993) (4)
EUSOMA guidelines on the management of familial breast cancer risk (2004) (4)
Season of initial detection in breast cancer. (1991) (4)
Relation of mastalgia to breast cancer (1982) (4)
Differential expression of estrogen-regulated genes in breast-cancer (1995) (4)
Place and training of the surgeon in breast cancer screening. (1989) (4)
Management of primary breast cancer in the elderly patient. (2003) (3)
Breast transillumination using the sinus diaphanograph. (1981) (3)
Cathepsin D reactivity in human breast carcinoma. Important prognostic factor or epiphenomenon (1992) (3)
The use of DNA typing to clarify the origin of metastatic carcinoma after renal transplantation (1994) (3)
Comments on NCI Alert on node-negative breast cancer (1989) (3)
The Nottingham Research Programme in breast cancer. (1984) (3)
The effect of some stilboestrol compounds on deoxyribonucleic acid polymerase from human and canine prostatic tissue. (1969) (3)
The diagnosis and prognosis of breast cancer. (1982) (3)
The Nottingham breast self-examination project. (1989) (3)
The use of the pelvic radiograph alone to assess therapeutic response in bone metastases from breast cancer. (1988) (3)
Results from a seven-year programme of breast self-examination in 89,010 women (1990) (3)
Tests of cell mediated immunity in patients with early breast cancer. I. Response to DNCB at time of mastectomy. (1978) (2)
The relationship of background mammographic pattern to hormone dependency in breast cancer (1984) (2)
O-62 External validation in ONCOPOOL of updated survival according to the Nottingham Prognostic Index (NPI) (2007) (2)
Steroid Receptors and Primary Breast Cancer: Their Prognostic Value (1984) (2)
Randomised trial comparing zoladex∗ with nolvadex∗ plus zoladex in pre-menopausal advanced breast cancer (1992) (2)
RECRUITMENT TO BREAST CANCER TRIALS (1984) (2)
98. Mammographic features of interval cancers and prognosis compared with screen detected and symptomatic breast cancers (1995) (2)
O-46 The prognosis of small breast cancers and selection for omission of adjuvant chemotherapy (2007) (2)
115 HER2 (cerbB2) positivity: cross correlations, and effect on survival of a pre-Herceptin treated group (2010) (2)
Mastectomy or conservation: the patient's choice. (1988) (2)
Availability of Organs for Transplantation: A Three Year Study (1987) (2)
The introduction of the LHRH agonist, Goserelin (Zoladex) into clinical practice (1997) (2)
Drugs for breast pain. (1981) (2)
The problems referred to a breast clinic. (1988) (2)
MANAGEMENT OF INTRA-DUCT CARCINOMA (1984) (2)
Comment on ‘Predicting recurrence in axillary node negative breast cancer patients’, by Rosner and Lane (1993) (2)
Advances in the management of metastatic bone disease (1994) (2)
DNA fingerprinting of benign and malignant breast lesions. (1996) (2)
Flap recurrence following simple mastectomy: an audit (1993) (2)
Localization of incompetent perforating vei by thermography. (1969) (1)
O-59 Identification of sub-classes of breast cancer through consensus derived from automated clustering methods (2007) (1)
Are you a typer, grader or a molecular convert? Prognostic assessment of operable breast carcinoma (1992) (1)
Oestrogen receptor content of primary breast tumours as a prognostic indicator of early recurrence [proceedings]. (1978) (1)
Drugs for breast pain. (1981) (1)
33. Small breast cancer: an integrated index is still important (1995) (1)
Value of breast imaging in women with painful breasts. Women with severe problems must be seen in specialist breast clinics. (1999) (1)
Atlas of breast cancer (1994) (1)
Age is not an independent prognostic factor (2001) (1)
Selective use of post-mastectomy flap irradiation in high-risk breast cancer patients. (2005) (1)
Epidermal Growth Factor Receptor (EGFR) expression: Prognostic value in breast cancer patients with long-term follow-up (2001) (1)
Higher degrees in surgical training a pre‐meeting workshop at the Surgical Research Society (1984) (1)
Proceedings: Primary breast cancer: identification of poor prognosis. (1976) (1)
Treatment of poor prognosis renal allograft rejection with anti-lymphocyte globulin (ALG) ― An analysis of late results (1988) (1)
Flow and static cytometry in the automated analysis of grading in breast cancer (1992) (1)
Measurement of the immune response to an allograft: Amino acid incorporation by peripheral white blood cells in man (1975) (1)
Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only (1993) (1)
Major problems in pathology volume II: Problems in breast pathology. J. G. Azzopardi. 268×188 mm. Pp. 466+xvi. Illustrated. 1979. Eastbourne: Saunders. £25·00. (1982) (1)
Improvement in HLA matching and graft survival achieved by organ sharing. (1991) (1)
2 Markers for diagnosis (1995) (1)
78. Subcutaneous mastectomy for primary breast cancer or ductal carcinoma in situ (1995) (1)
Surgery versus tamoxifen in selected elderly patients with operable breast cancer: Early results of a randomised trial (1992) (1)
The rates of growth of breast cancers (2004) (1)
The BASO II trial of primary treatment of tumours of excellent prognosis (2006) (1)
The Feulgen hydrolysis profile and breast carcinoma: a preliminary study. (1988) (1)
19. Selection criteria for breast conservation in primary operable invasive breast cancer (1995) (1)
Corrigendum to “ONCOPOOL – A European database for 16,944 cases of breast cancer” [European Journal of Cancer 46 (2009) 56–71] (2010) (1)
Tables of anticipated benefit from adjuvant therapy for the individual (2001) (1)
Breast cancer screening: A benefit can be anticipated (1992) (1)
Multimodal treatment in operable breast cancer (1983) (1)
Non-operative management of discrete palpable breast lumps in women over 35 years of age (1992) (1)
Factors underlying the improvement in mortality from breast cancer (2001) (1)
Effect of acute damage from acute rejection and ischemia on long-term renal allograft histology. (1993) (1)
Histological grade in predicting response to endocrine treatment (2005) (1)
Frequency of screening for breast cancer (1989) (1)
Safe criteria for breast conservation without radical excision (1993) (1)
OUTCOME INDICATORS FOR BREAST CANCER (1999) (1)
Randomised clinical trials in breast cancer (1992) (1)
Non-operation of discrete solid palpable breast lumps in women over 35 years of age is safe (1993) (0)
Mammographic screening for breast cancer. Significant reduction in recall and benign biopsy rates associated with the introduction of set management policies (1992) (0)
P163 The prognosis of small breast cancers (2007) (0)
Book Review: Access Surgery: A Review of Current Techniques for Vascular Access for Haemodialysis, Chemotherapy and Total Parenteral Nutrition (1983) (0)
35. Comparability of prognostic indices (1995) (0)
Primary management of breast cancer: Alternatives to mastectomy. J. S. Tobias and M. J. Peckham. 240 × 160 mm. Pp. 220 + xvii. Illustrated in black and white. 1985. London: Edward Arnold Ltd. £32.50 (1986) (0)
O-9 ONCOPOOL – A European Database in 16,893 cases of breast cancer: comparison with SEER (2007) (0)
Reticulo‐endothelial system activity during homograft rejection and immunosuppression (1972) (0)
Reply to Editorial Comment (2002) (0)
1039 Post-mastectomy radiotherapy (RT) in high-risk patients (1995) (0)
Can sentinel node biopsy improve prognostic discrimination (2002) (0)
Proceedings: Renal and skin allograft rejection in presensitized animals. (1974) (0)
DNA ploidy in fibroadenomas (abstract). (1989) (0)
Breast cancer screening: counter editorial. (1989) (0)
theimportanceof chronic rejection as a cause of gra t loss (1989) (0)
Transabdominal bilateral adrenalectomy for metastatic breast cancer. (1980) (0)
Author's response: Reply from Professor R. W. Blamey (1985) (0)
Author Index/Subject Index (2020) (0)
Invasive micropapillary carcinoma of the breast (2000) (0)
O-63 Survival in East Anglia according to the Nottingham Prognostic Index (2007) (0)
re: Family history screening and breast cancer (1997) (0)
Points: Urological complications of renal transplantation (1982) (0)
The effect on survival of local recurrence (LR) after breast conserving surgery (2006) (0)
O-20 Rates of growth of breast cancer (2010) (0)
Investigation of a novel pure antioestrogen in women with primary breast cancer (1993) (0)
Epidermal Growth Factor Receptor Status in Operable Invasive Breast Cancer (2004) (0)
O-3 Long-term results from the ZEBRA trial comparing Goserelin with CMF as adjuvant therapy in premenopausal women (2007) (0)
LH-RH Agonists for the Treatment of Breast Cancer (2009) (0)
BREAST RECONSTRUCTION AFTER SUBCUTANEOUS MASTECTOMY (1979) (0)
The genetic fingerprinting of breast cancers (1992) (0)
HISTOLOGICAL GRADE AND RESPONSE TO ENDOCRINE THERAPY IN BREAST CANCER (1981) (0)
Morbidity from lymphoedema following treatment of primary breast cancer (2003) (0)
Screening for contralateral breast cancer — is it worthwhile? (1993) (0)
Phyllodes tumors of the breast histological features and clinical behavior (1991) (0)
Axillary lymph node metastases from clinically occult breast carcinoma. (1987) (0)
Post-mastectomy reconstruction. T. D. Gant and L. O. Vasconez. 260 × 175 mm. Pp. 179 + x. Illustrated. 1981. Baltimore: Williams & Wilkins (1981) (0)
Contents, Supplement 2, 1997 (1997) (0)
Single duct discharge from the nipple (1989) (0)
Measurement of lymphocyte activity in response to a renal allograft. (1973) (0)
Discussion paper — sentinel node biopsy: Hope or hype? (2001) (0)
Roger Ernest Cotton (2006) (0)
60. Radiotherapy may be unnecessary after adequate local excision of ductal carcinoma in situ (1995) (0)
Fulvestrant: A Viewpoint by Roger W. Blamey (2001) (0)
Hormonochemotherapy in advanced breast cancer (1987) (0)
The silent majority — meeting the emotional needs of women with a negative diagnosis — the results of a patient survey (1993) (0)
Breast screening in Scandinavia (1990) (0)
O-72 Remodeling the Nottingham Prognostic Index (NPI) for individual prognosis (2010) (0)
D-1 Absolute Gain (2007) (0)
54. The assessment of multiple variables on preoperative opeast carcinoma fine needle aspiration cytology specimens (1995) (0)
Where Bench and Field Sciences Meet: Molecular Epidemiology at NIEHS (1994) (0)
Breast cancer. The facts. Michael Baum. 223 × 140 mm. Pp. 111 + ix. Illustrated. 1981. Oxford: Oxford Univ. Press. £4.95 (1983) (0)
Prognostic value of immunocytochemistry of the primary tumour in patients with metastatic breast cancer (1995) (0)
Proceedings: Lymphocyte capacity and lymphoblast circulation in immune stimulation and immunosuppression. (1976) (0)
erbB Signalling in breast cancer (2007) (0)
The ZEBRA study: Zoladex™ is as effective as CMF in pre-/perimenopausal patients with oestrogen receptor positive, node-positive early breast cancer (2001) (0)
0-41. An update on breast screening for women aged < 50: results from a family history clinic (1997) (0)
O-105 erbB Signalling in breast cancer (2007) (0)
Screening the at risk patient: family history (1993) (0)
9 The initial approach to tumour markers in guiding therapy (1995) (0)
DNA ploidy and proliferative index in breast cancer prognosis (1992) (0)
Correspondence (1979) (0)
Prediction of survival in the individual with breast cancer. (1999) (0)
O-71 Rescoring of grade and re-evaluation of the Nottingham Prognostic Index (NPI) using components of Elston Ellis grade and adding lympho-vascular invasion (2010) (0)
Reading the prognosis of the individual according to the exact NPI value (2004) (0)
Comment on ‘New lumps in the breast following conservation treatment for early breast cancer’ (1988) (0)
Measurement of the immune response to a renal allograft. I. Evaluation of changes in lymphocyte activity in the rat. (1973) (0)
0-59. The National health service breast screening programme in the trent region — are we meeting the targets? (1997) (0)
A REVIEW FROM THE BRITISH ASSOCIATION OF SURGICAL ONCOLOGY (1999) (0)
PP-6-7 Automated grading in a prognostic index (1996) (0)
146 ONCOPOOL, a comparison with SEER (2010) (0)
Generic substitution (1983) (0)
Survey of patient opinion on the retrospective use of their tissues for research (2004) (0)
AVAILABILITY OF KIDNEY DONORS IN THE TRENT REGION (1981) (0)
Representation of hospital junior doctors (1969) (0)
PP-6-6 The Prognostic Importance of Tumour Grade in Lymph Node Positive Breast Cancer (1996) (0)
The frequency of breast cancer screening: results of a randomised trial (2004) (0)
An Inexpensive Zoom Double Operating Microscope System (1977) (0)
Therapeutic Aspects of Screen-Detected Lesions: The Role of the Surgeon (1993) (0)
ONCOPOOL — A European dataset in 16,893 cases of breast cancer (2006) (0)
Confirmation of a prognostic index for breast cancer (1992) (0)
51. Angiogenesis in human breast carcinoma (1995) (0)
A computer programme to calculate for the individual the expected improvement in survival chance from adjuvant therapies (2004) (0)
The prognostic significance of inflammation in invasive carcinoma of the breast (2006) (0)
Marker biopsy of 268 impalpable breast lesions: An audit of the radiological, pathological and surgical aspects (1992) (0)
Metallothionein expression inhumanbreast cancer (1995) (0)
Reticulo-endothelial system (R.E.S.) activity during immunosuppression. (1968) (0)
cancer ABC of breast diseases : Screening for breast (2000) (0)
A Clinical Database for the Study op Prognostic Factors in Breast Cancer (1985) (0)
Comment on prognosis in node negative breast cancer (1987) (0)
Breast Disease is now a Specialist Discipline (2006) (0)
Influence ofAnti-Oestrogens ontheSpecific Binding invitro ofL3HlOestradiol by Cytosol ofRatMammaryTumours andHumanBreast Carcinomata (1975) (0)
Basic and clinical immunology. Edited H. H. Fudenberg, D. P. Stites, J. L. Caldwell and J. V. Wells. Second edition. 255 × 180 mm. Pp. 758. Illustrated. 1978. California: Lange. $14.50 (1979) (0)
Combination chemotherapy in breast cancer: response rate and attempts to predict response. (1979) (0)
E3. The impact of surgical techniques on quality of life (2002) (0)
Sentinel node biopsy versus axillary node sampling in axillary staging (1999) (0)
The effect of screening on mortality (2004) (0)
Further comment on ‘complete response’ in breast cancer treatment (1986) (0)
Updated survival analyses from the ZEBRA study: goserelin vs CMF in premenopausal women with node-positive breast cancer (2003) (0)
O-68 The effect of lymphovascular invasion (LVI) on survival (2010) (0)
The formation of membrane-bound glycoproteins by explants of malignant human breasttissue (1984) (0)
Atlas of Breast Pathology. Folke Linell and Otto Ljungberg. 250 ± 175 mm. Pp. 305. Illustrated in black and white and colour. 1984. Copenhagen: Munksgaard Internat. 570.00 D.kr. (1985) (0)
Zoladex plus tamoxifen versus zoladex alone in premenopausal metastatic breast cancer (1990) (0)
The short-term effects of cadaveric kidney exchange via a beneficial matching scheme. (1991) (0)
The operative management of breast disease R. R. Baker and J. Niederhuber. 285 × 220 mm. Pp. 135. Illustrated. 1992. Philadelphia, Pennsylvania: W. B. Saunders. £83 (1993) (0)
The Nottingham proceedings : selected papers from the Nottingham International Breast Cancer Meeting, September 1990 (1991) (0)
Localization of incompetent veins by thermography. (1969) (0)
Pinning down the diagnosis in breast cancer. (1977) (0)
Seventeenth Sir Peter Freyer memorial lecture and surgical symposium (1994) (0)
O-47 The BASO II trial at median 15 years of follow-up (2010) (0)
TRAFFIC OF LYMPHOCYTES IN THE THORACIC DUCT AND RENAL LYMPH AFTER ALLOTRANSPLANTATION AND IN IMMUNOSUPPRESSION (1978) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roger W. Blamey?

Roger W. Blamey is affiliated with the following schools: